Skip to content

Diebold Nixdorf DBD Accrued Compensation

Accrued Compensation at other companies

Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
-$15.02M-4.2%
Tetra Tech logo
Tetra TechTTEK
-$126.66M-24.6%
Corvex
 logo
Corvex MOVE
$364K+17.8%
Kimberly-Clark logo
Kimberly-ClarkKMB
$284M-27.9%
Samsara logo
SamsaraIOT
$59.58M+36.4%
Kenvue logo
KenvueKVUE
$345M-1.4%

Other financials

Income statement

See full
Revenue$891.8M+6.0%
Gross profit$213.1M+5.3%
Operating income$32.7M+10.5%
Net income$5.0M+160%
EPS (diluted)$0.14+164%

Balance sheet

See full
Cash & equivalents$373.6M+16.7%
Total debt$994.8M-5.7%
Total equity$1.0B+4.0%
Total assets$3.8B+5.6%

Cash flow

See full
Operating cash flow$31.7M+102%

Valuation

See full
Market cap$2.86B+61.3%
Enterprise value$3.48B+37.6%
P/E26.5×
P/S0.7×+0.3×

Profitability

See full
Gross margin25.2%+0.5pp
Operating margin6.4%+1.3pp
Net margin2.8%

Returns & leverage

See full
Return on equity10.8%
Debt / equity-0.1×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Diebold Nixdorf in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedSalaries.

The official record: Diebold Nixdorf’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Diebold Nixdorf's accrued compensation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Diebold Nixdorf's accrued compensation?
Diebold Nixdorf (DBD) reported accrued compensation of -$28.7M in Q1 2026.
How has Diebold Nixdorf's accrued compensation changed year-over-year?
Diebold Nixdorf's accrued compensation decreased by 10.4% year-over-year, from -$26M to -$28.7M.
What is the long-term trend for Diebold Nixdorf's accrued compensation?
Over 2 years (2022 to 2024), Diebold Nixdorf's accrued compensation has grown at a -36.8% compound annual growth rate (CAGR), from -$72.5M to $29M.